Tetsuya Nishida
Overview
Explore the profile of Tetsuya Nishida including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
120
Citations
1393
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nagayama T, Fujiwara S, Nishiwaki S, Wada F, Uchida N, Tanaka M, et al.
Blood Adv
. 2025 Mar;
PMID: 40085961
Allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-matched donors is the gold standard. However, haploidentical stem cell transplantation using posttransplant cyclophosphamide (PTCY-haplo) and cord blood transplants (CBTs) are alternatives when...
2.
Misaki Y, Tamaki M, Yanagisawa R, Doki N, Uchida N, Tanaka M, et al.
Am J Hematol
. 2025 Mar;
PMID: 40056058
Although the hematopoietic cell transplantation (HCT)-comorbidity index (HCT-CI) score is associated with an increased risk of mortality after allogeneic HCT, it remains unclear how pre-HCT liver dysfunction affects clinical outcomes....
3.
Mitsuyoshi T, Arai Y, Kondo T, Kawata T, Hirabayashi S, Tanaka M, et al.
EJHaem
. 2025 Jan;
6(1):e21088.
PMID: 39866933
Introduction: Understanding differences in clinical outcomes between PBSCT and BMT is important, and this study compared outcomes of HLA-matched related PBSCT and BMT using reduced-intensity conditioning (RIC) in adult acute...
4.
Oshima S, Arai Y, Kondo T, Yano S, Hirabayashi S, Uchida N, et al.
Bone Marrow Transplant
. 2025 Jan;
PMID: 39838078
Umbilical cord blood transplantation (CBT) is accepted as an effective treatment for acute myeloid leukemia (AML), and reduced-intensity conditioning (RIC), rather than myeloablative conditioning (MAC) regimens allowed elderly patients to...
5.
Nishiwaki S, Terakura S, Morishita T, Goto T, Inagaki Y, Miyao K, et al.
Int J Hematol
. 2025 Jan;
PMID: 39821010
Post-transplant tyrosine kinase inhibitors (TKIs) show promise in preventing relapse after allogeneic hematopoietic cell transplantation (allo-HCT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). However, their real-world use and efficacy remain...
6.
Kawamura S, Nakagawa D, Nagayama T, Katayama Y, Doki N, Takeda W, et al.
Blood Adv
. 2025 Jan;
PMID: 39808797
In unrelated allogeneic hematopoietic cell transplantation (allo-HCT), older and/or HLA-mismatched donors are known risk factors for survival outcomes. In healthy individuals, cytomegalovirus (CMV) seropositivity is associated with impaired adaptive immune...
7.
Mitsuyuki S, Shimomura Y, Mizumaki H, Yanada M, Mizuno S, Uchida N, et al.
Leukemia
. 2024 Dec;
39(2):495-498.
PMID: 39658629
No abstract available.
8.
Jo T, Inoue K, Ueda T, Iwasaki M, Akahoshi Y, Nishiwaki S, et al.
Commun Med (Lond)
. 2024 Nov;
4(1):247.
PMID: 39587218
Background: The advantage of intensified myeloablative conditioning (MAC) over standard MAC has not been determined in haematopoietic stem cell transplantation (HSCT) for adult acute lymphoblastic leukemia (ALL) patients. Methods: To...
9.
Konuma T, Kameda K, Morita K, Kondo T, Kimura F, Nakasone H, et al.
Am J Hematol
. 2024 Nov;
100(1):66-77.
PMID: 39564683
We retrospectively evaluated the impacts of using granulocyte colony-stimulating factor (G-CSF) and its timing on posttransplant outcomes for 9766 adults with acute myeloid leukemia (AML) between 2013 and 2022 using...
10.
Mizuno S, Hosoi H, Takami A, Kawata T, Doki N, Takeda W, et al.
Ann Hematol
. 2024 Nov;
103(12):5903-5913.
PMID: 39560740
This study aimed to investigate the prognostic relevance of cytogenetic risk in 9826 adults with acute myeloid leukemia (AML) who underwent allogeneic hematopoietic cell transplantation (HCT) during the first or...